Nanogen

Seite 1 von 1
neuester Beitrag: 19.03.01 23:24
eröffnet am: 19.03.01 19:05 von: BigBrooker Anzahl Beiträge: 4
neuester Beitrag: 19.03.01 23:24 von: Kicky Leser gesamt: 1439
davon Heute: 2
bewertet mit 0 Sternen

19.03.01 19:05

63 Postings, 8071 Tage BigBrookerNanogen

was is den da los ???
+ 20% :-))  

19.03.01 19:12

2509 Postings, 8465 Tage HiobSchau Dir einfach mal an, wie die in den

letzten Monaten nachgegeben haben. Im Vergleich dazu sind diese jetzt 25% Plus gar nichts. Ob die sich jemals wieder erholen und auch nur annähernd zu einstigen Höhen aufsteigen können, ist nur schwer zu prognostizieren. Denn die Firma agiert auf einem umkämpften und riskanten Markt (Genchips), auf dem es unkalkulierbare Verschiebungen geben kann. Momentan würde ich daher nicht unbedingt auf NGEN.NAS setzen.  

19.03.01 20:04

63 Postings, 8071 Tage BigBrookerNanogen nein Danke ??

Hmm, meinte es gibt irgendwelche news, denn ich hab sie dieses Monat 3x
gehandelt, so zu 6,20 rein und bei 6,40 - 6,70 raus. Auch Kleinvieh macht mist! Diesmal bin ich bei 6,40 rein und bei 7.80 raus, meist 700-1000stk .Also wieso diesen Wert nicht handeln ???  

19.03.01 23:24

75892 Postings, 8435 Tage KickyBeta Testing des Nanochip +30% heute

Thursday March 15, 2001 07:01 AM
Company Press Release

SOURCE:Nanogen, Inc.


Nanogen Begins Beta Testing of its NanoChip(TM) Molecular Biology Workstation For Targeted Gene Expression Applications

Also Announces 384 Well Plate Capability for Increased Automation
SAN DIEGO, March 15 /PRNewswire/ -- Nanogen, Inc. (Nasdaq: NGEN), producer of the only commercially available system for electronically controlled DNA reactions on microchips, announced today that it has entered into agreements with three institutions to begin beta testing of its NanoChip(TM) Molecular Biology Workstation for targeted gene expression applications. Two of the institutions have already begun gene expression beta tests and the third will start within the next two weeks. Two of the institutions are in the United States and one is in Europe.

Nanogen selected the institutions based on the quality of their research in the expression of individual genes and groups of genes related to cancer, neurological disorders, diabetes and other diseases, and on their experience with using various competitive gene expression technologies. The Company plans to utilize the data, results and feedback from the beta tests to increase the versatility of the NanoChip(TM) System by allowing researchers to use the system for gene expression applications in addition to the applications for which the system is currently sold, namely the detection and analysis of single nucleotide polymorphisms (SNPs), short tandem repeats (STRs) and hard-to-score mutations. Unlike most commercial gene expression techniques, Nanogen's is designed for scientists needing quantitative, reproducible assays with a known set of genes. These scientists will be looking for the capability to perform time-series studies with multiple samples on a single chip or across multiple chips.

Nanogen also announced that it has expanded the capability of the NanoChip(TM) System by upgrading its Loader to utilize either a 384 well plate or a 96 well plate. The larger 384 well plate is designed to improve productivity in the lab by increasing unattended automation and throughput.

jedoch Volumen fällt schon wieder,trotzdem über die 13 Tagelinie gelaufen,wird vermutlich leicht konsolidieren
 

   Antwort einfügen - nach oben